ADPD 2026: Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease | Prothena Corporation plc

Skip to main content

ADPD 2026: Presentations on Prasinezumab for the Potential Treatment of Parkinson’s Disease

March 21, 2026 8:00 AM GMT

Copenhagen, Denmark

Oral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’ (opens in new window)
Oral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study (opens in new window)
Poster Presentation – Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s Disease: Findings from the PADOVA Phase IIb Study (opens in new window)
Poster Presentation – Sustained Effect on Prasinezumab on Parkinson’s Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update (opens in new window)
Poster Presentation – Digital Health Technology Detects Group Differences in Practically-Defined OFF L-DOPA State: Results of PADOVA Phase IIb Study of Prasinezumab (opens in new window)